A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

Marc Uemura; Faa'k Faisal; Cara Haymaker; Natalie McQuail; Elizabeth Sirmans; Courtney W. Hudgens; Lydia Barbara; Chantale Bernatchez; Jonathan L. Curry; Patrick Hwu; Michael T. Tetzlaff; Adi Diab

doi:10.1186/s40425-016-0157-6

A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

Marc Uemura, Faa'k Faisal, Cara Haymaker, Natalie McQuail, Elizabeth Sirmans, Courtney W. Hudgens, Lydia Barbara, Chantale Bernatchez, Jonathan L. Curry, Patrick Hwu, Michael T. Tetzlaff, Adi Diab

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

Background: Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover's disease is an uncommon dermatologic condition with unclear pathogenesis previously reported as an irAE with ipilimumab. Case Presentation: We report an additional case of ipilimumab-induced Grover's disease. Interestingly, this dermatologic side effect did not appear with use of anti-PD-1 therapy in our patient. Immune analysis was performed and suggests a possible role of Th2 cells in its patholgenesis. Conclusion: This case suggests that Grover's disease is an irAE induced by Ipilimumab. Our immune analysis suggests that Th2 cells may be pathogenic mediators which warrants further study.

Original language	English (US)
Article number	55
Journal	Journal for immunotherapy of cancer
Volume	4
Issue number	1
DOIs	https://doi.org/10.1186/s40425-016-0157-6
State	Published - Sep 20 2016

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Molecular Medicine
Oncology
Pharmacology
Cancer Research

Access to Document

10.1186/s40425-016-0157-6

Cite this

Uemura, M., Faisal, F., Haymaker, C., McQuail, N., Sirmans, E., Hudgens, C. W., Barbara, L., Bernatchez, C., Curry, J. L., Hwu, P., Tetzlaff, M. T., & Diab, A. (2016). A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. Journal for immunotherapy of cancer, 4(1), Article 55. https://doi.org/10.1186/s40425-016-0157-6

@article{66508c67a11249ff91c78d536e73422c,

title = "A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1",

abstract = "Background: Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover's disease is an uncommon dermatologic condition with unclear pathogenesis previously reported as an irAE with ipilimumab. Case Presentation: We report an additional case of ipilimumab-induced Grover's disease. Interestingly, this dermatologic side effect did not appear with use of anti-PD-1 therapy in our patient. Immune analysis was performed and suggests a possible role of Th2 cells in its patholgenesis. Conclusion: This case suggests that Grover's disease is an irAE induced by Ipilimumab. Our immune analysis suggests that Th2 cells may be pathogenic mediators which warrants further study.",

author = "Marc Uemura and Faa'k Faisal and Cara Haymaker and Natalie McQuail and Elizabeth Sirmans and Hudgens, {Courtney W.} and Lydia Barbara and Chantale Bernatchez and Curry, {Jonathan L.} and Patrick Hwu and Tetzlaff, {Michael T.} and Adi Diab",

note = "Publisher Copyright: {\textcopyright} 2016 The Author(s).",

year = "2016",

month = sep,

day = "20",

doi = "10.1186/s40425-016-0157-6",

language = "English (US)",

volume = "4",

journal = "Journal for immunotherapy of cancer",

issn = "2051-1426",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

AU - Uemura, Marc

AU - Faisal, Faa'k

AU - Haymaker, Cara

AU - McQuail, Natalie

AU - Sirmans, Elizabeth

AU - Hudgens, Courtney W.

AU - Barbara, Lydia

AU - Bernatchez, Chantale

AU - Curry, Jonathan L.

AU - Hwu, Patrick

AU - Tetzlaff, Michael T.

AU - Diab, Adi

PY - 2016/9/20

Y1 - 2016/9/20

N2 - Background: Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover's disease is an uncommon dermatologic condition with unclear pathogenesis previously reported as an irAE with ipilimumab. Case Presentation: We report an additional case of ipilimumab-induced Grover's disease. Interestingly, this dermatologic side effect did not appear with use of anti-PD-1 therapy in our patient. Immune analysis was performed and suggests a possible role of Th2 cells in its patholgenesis. Conclusion: This case suggests that Grover's disease is an irAE induced by Ipilimumab. Our immune analysis suggests that Th2 cells may be pathogenic mediators which warrants further study.

AB - Background: Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover's disease is an uncommon dermatologic condition with unclear pathogenesis previously reported as an irAE with ipilimumab. Case Presentation: We report an additional case of ipilimumab-induced Grover's disease. Interestingly, this dermatologic side effect did not appear with use of anti-PD-1 therapy in our patient. Immune analysis was performed and suggests a possible role of Th2 cells in its patholgenesis. Conclusion: This case suggests that Grover's disease is an irAE induced by Ipilimumab. Our immune analysis suggests that Th2 cells may be pathogenic mediators which warrants further study.

UR - http://www.scopus.com/inward/record.url?scp=84997712026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997712026&partnerID=8YFLogxK

U2 - 10.1186/s40425-016-0157-6

DO - 10.1186/s40425-016-0157-6

M3 - Article

C2 - 27660709

AN - SCOPUS:84997712026

SN - 2051-1426

VL - 4

JO - Journal for immunotherapy of cancer

JF - Journal for immunotherapy of cancer

IS - 1

M1 - 55

ER -

A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this